By: Benzinga
Pfizer Wins FDA Approval for Use of Prevnar 13 in Vaccine-Naive Children, Adolescents Aged 6-17 for Prevention of Invasive Pneumococcal Disease
Pfizer Inc. (NYSE: PFE ) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13^®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM[197] Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here